Case Study
Buch Pharmaceutical Group (BPG) is a B2B pharmaceutical organization operating in a highly regulated and trust-driven industry. Like most pharma brands, BPG’s digital presence had historically been minimal — the LinkedIn page existed, but with negligible organic traction, no consistent content strategy, and a following that reflected years of inactivity rather than growth.
In the pharmaceutical sector, LinkedIn is not just a social channel — it is the primary credibility signal for partners, procurement teams, healthcare professionals, and institutional buyers. A weak LinkedIn presence means missed business development opportunities and reduced brand authority in competitive tenders and partnership discussions.
In the pharmaceutical industry, content cannot be generic. Every post must build genuine authority while navigating regulatory constraints, industry terminology, and the expectations of a highly educated, skeptical B2B audience. Most agencies fail in pharma because they apply consumer social media playbooks to an audience that demands something very different.
We built BPG’s LinkedIn presence around a single principle: pharmaceutical credibility cannot be faked — it must be earned through consistent, well-researched, professionally presented content. Our approach combined content strategy, publishing cadence, and audience growth tactics designed specifically for a B2B regulated industry environment.
We structured BPG’s content around four core pillars designed to build authority at every stage of the decision-making journey:
We moved BPG from sporadic posting to a structured weekly publishing schedule, ensuring the LinkedIn algorithm received consistent signals and followers had regular reasons to engage. Content was planned in advance using an editorial calendar aligned with industry events, regulatory cycles, and seasonal business conversations.
With zero paid spend, all 1,558 new followers were generated organically through a combination of content quality, strategic hashtag use, employee amplification, and consistent publishing. The follower growth chart shows a significant acceleration from February 2026 onward — a direct result of compounding content authority built over the preceding eight months.
Each post was crafted with specific engagement triggers — questions, polls, data-led hooks, and industry debates — designed to generate reactions and comments from a professional audience. The engagement rate of 3.6% is notably strong for a B2B pharmaceutical page, where industry benchmarks typically sit between 1–2%.
Call-to-action strategies were embedded in high-performing content to drive visitors from the feed to the BPG company page and website. The combination of desktop (512) and mobile (603) visitors reflects a genuinely engaged professional audience accessing content across contexts — not just passive scrolling.
Let's get started
Whether you operate in a regulated industry or a competitive B2B space, Braineax builds LinkedIn strategies that generate real reach, real engagement, and real business development opportunities — without shortcuts.
